Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotid
Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.
대표청구항▼
1. A method for introducing an intact oligonucleotide into a mammal comprising the step of orally administering an oligonucleotide of about 15 to about 25 nucleotides, wherein the oligonucleotide comprises at least one phosphorothioate internucleotide linkage, and further comprises at least one 2'-O
1. A method for introducing an intact oligonucleotide into a mammal comprising the step of orally administering an oligonucleotide of about 15 to about 25 nucleotides, wherein the oligonucleotide comprises at least one phosphorothioate internucleotide linkage, and further comprises at least one 2'-O-methoxyethyl ribonucleotide at the 5' terminus and at least one 2'-O-methoxyethyl ribonucleotide the 3' terminus, wherein the oligonucleotide is present in intact form in the systemic plasma and liver tissue of the mammal at least six hours following oral administration. 2. The method of claim 1, wherein the oligonucleotide comprises at least two 2'-O-methoxyethyl ribonucleotides at the 3' terminus. 3. The method of claim 1, wherein the oligonucleotide comprises at least two 2'-O-methoxyethyl ribonucleotides at the 5' terminus. 4. The method of claim 1, wherein the oligonucleotide comprises a phosphorothioate internucleotide linkage between every nucleotide. 5. A method for introducing an intact oligonucleotide into a mammal comprising the step of orally administering an oligonucleotide of about 15 to about 25 nucleotides, wherein the oligonucleotide comprises at least one phosphorothioate internucleotide linkage, and further comprises at least two 2'-O-methoxyethyl ribonucleotides at the 5' terminus and at least two 2'-O-methoxyethyl ribonucleotides the 3' terminus, wherein the oligonucleotide is present in intact form in the systemic plasma and liver tissue of the mammal at least six hours following oral administration. 6. The method of claim 5, wherein the oligonucleotide comprises a phosphorothioate internucleotide linkage between every nucleotide. 7. The method of claim 1, wherein the oligonucleotide further comprises at least one alkylphosphonate internucleotide linkage. 8. The method of claim 1, wherein the oligonucleotide further comprises at least one alkylphosphonate internucleotide linkage. 9. A method for introducing an intact oligonucleotide into a mammal comprising the step of orally administering an oligonucleotide of about 15 to about 25 nucleotides, wherein the oligonucleotide comprises at least one phosphorothioate internucleotide linkage, and further comprises at least one 2'-O-(C1-C6alkyl) ribonucleotide at the 5' terminus, wherein the (C1-C6alkyl) is substituted with an alkoxy group, and at least one 2'-O-(C1-C6alkyl) ribonucleotide at the 3' terminus, wherein the (C1-C6alkyl) is substituted with an alkoxy group, and wherein the oligonucleotide is present in intact form in the systemic plasma and liver tissue of the mammal at least six hours following oral administration. 10. The method of claim 9, wherein the oligonucleotide comprises at least two 2'-O-(C1-C6alkyl) ribonucleotides at the 5' terminus, wherein the two (C1-C6alkyl) groups are substituted with an alkoxy group. 11. The method of claim 9, wherein the oligonucleotide comprises at least two 2'-O-(C1-C6alkyl) ribonucleotide at the 3' terminus, wherein the two (C1-C6alkyl) groups are substituted with an alkoxy group. 12. The method of claim 9, wherein the oligonucleotide comprises at least two 2'-O-(C1-C6alkyl) ribonucleotides at the 5' terminus, wherein the (C1-C6alkyl) is substituted with an alkoxy group; and at least two 2'-O-(C1-C6alkyl) ribonucleotide at the 3' terminus, wherein the (C1-C6alkyl) is substituted with an alkoxy group. 13. The method of claim 9, wherein the oligonucleotide further comprises at least one alkylphosphonate internucleotide linkage. 14. The method of claim 9, wherein the oligonucleotide comprises a phosphorothioate internucleotide linkage between every nucleotide.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Draper Kenneth G. (San Marcos CA) Ecker David J. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Crooke Stanley T. (Carlsbad CA), Antisense oligonucleotides for inhibiting herpesviruses.
Porter Stuart C. (Hatfield PA) Woznicki Edward J. (Douglassville PA) Grillo Susan M. (North Wales PA) D\Andrea Louis F. (King of Prussia PA), Enteric film-coating compositions.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Draper Kenneth G. (Boulder CO) Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Leucadia CA) Hanecak Ronnie C. (San Clemente CA) Anderson Kevin P. (Carlsbad CA), Oligonucleotide therapies for modulating the effects of herpes viruses.
Anderson Kevin (Carlsbad CA) Draper Kenneth (Boulder CO) Baker Brenda (Encinitas CA), Oligonucleotides for modulating the effects of cytomegalovirus infections.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.